Alverine Citrate: Uses, How It Works, and Side Effects

Alverine citrate is a smooth muscle relaxant prescribed mainly to relieve abdominal pain and cramping caused by irritable bowel syndrome (IBS) and, in some countries, painful menstrual cramps. It works through a somewhat unusual dual mechanism, acting on both the gut muscle itself and the nerve signaling that makes the gut overly sensitive to pain. The clinical evidence supporting it is genuinely mixed, though, and its strongest results come from a combination formulation rather than the drug on its own.

What Alverine Citrate Is Prescribed For

Alverine citrate belongs to a class of drugs called antispasmodics, which are designed to calm the involuntary contractions of smooth muscle in the digestive tract. Its primary approved use is for IBS, specifically the abdominal pain and discomfort that define the condition for most patients. In several European countries, it is also prescribed for dysmenorrhea (painful periods), since the uterus is lined with smooth muscle that responds to the same kind of relaxant. It is not typically used for structural gut diseases like inflammatory bowel disease or for post-surgical pain.

In the UK, alverine citrate is available as a prescription medication under the brand name Spasmonal, usually in 60 mg or 120 mg capsules taken up to three times daily. In France and several other European markets, it is most commonly sold as a fixed-dose combination with simeticone (an anti-gas agent), which has become the better-studied formulation in recent years. It is not approved or widely available in the United States.

How It Works on Gut Muscle

Most antispasmodics work in a fairly straightforward way: they block the signals that tell smooth muscle to contract, so the muscle relaxes. Alverine citrate does something more layered. Research into its mechanism has revealed that rather than simply preventing muscle contraction, alverine acts on the contractile machinery inside the muscle cell itself. Specifically, it reduces the sensitivity of smooth muscle proteins to calcium, the mineral that triggers contraction. The effect resembles what happens when you block an enzyme pathway called Rho kinase, which is involved in sustaining muscle tension.

Lab studies found that alverine at working concentrations could suppress contractions triggered by high potassium or the neurotransmitter acetylcholine, even without fully blocking the underlying electrical activity or calcium entry into the cell. This suggests it is interrupting contraction at a later stage than many other antispasmodics, which tend to act more like simple calcium-channel blockers.¹ The practical implication is that alverine may be better suited to calming the overactive, rhythmic contractions seen in IBS rather than just dampening all gut motility.

The Serotonin Connection

The gut contains an enormous amount of serotonin, and serotonin receptors play a major role in how sensitive your intestines are to stretching, gas, and movement. One reason IBS hurts so much is that the gut becomes hypersensitive: normal amounts of gas or normal contractions register as pain. This phenomenon is called visceral hypersensitivity, and it is a core feature of IBS that simple muscle relaxation alone does not fully address.

Alverine citrate turns out to have a second, quite different action: it binds with high affinity to 5-HT1A serotonin receptors and acts as a selective antagonist there. In animal studies, this blocked the gut hypersensitivity induced by serotonin precursors, meaning the gut went back to responding to stimuli at a more normal threshold.² In practical terms, this means alverine is not just relaxing the muscle; it is also dialing down the pain signals that make IBS patients feel crampy and uncomfortable even when the gut is doing relatively normal things.

This dual mechanism, targeting both the motor side (muscle contraction) and the sensory side (pain signaling), is a distinguishing feature that separates alverine from simpler antispasmodics. A recent review of abdominal pain management in IBS specifically highlighted this combined action as the rationale behind the alverine citrate/simeticone formulation.³

What Happens After You Swallow a Capsule

Alverine citrate is absorbed quickly after an oral dose, but here is something unusual: the parent drug almost immediately gets converted into a metabolite. According to pharmacokinetic data reviewed by the European Medicines Agency, alverine itself accounts for only about 3% of the drug-related material circulating in your blood. The overwhelming majority, around 94%, is a metabolite called 4-hydroxy alverine (in both free and conjugated forms). This primary metabolite reaches peak levels between one and one and a half hours after dosing.⁴

The metabolites are cleared through the kidneys by active secretion, which means they are pumped out rather than passively filtered. This rapid and thorough metabolism explains why alverine does not tend to accumulate with repeated dosing and partly accounts for its generally favorable side-effect profile. It also means that the drug’s activity in the body depends heavily on whether the metabolites retain the parent compound’s pharmacological effects, something that has not been completely characterized in published literature.

Clinical Evidence for IBS

This is where alverine citrate’s story gets complicated, because the clinical trial results do not all point in the same direction. The distinction between alverine on its own and alverine combined with simeticone matters a lot.

Alverine Alone

A double-blind, placebo-controlled trial tested alverine citrate by itself in IBS patients and found it was no better than placebo. Pain severity improved in about two-thirds of patients in both the alverine and placebo groups, and the average reduction in pain scores, while slightly larger with alverine (roughly 44% versus 33%), did not reach statistical significance.⁵ That is a sobering result, especially given how strong the placebo response tends to be in IBS trials generally. IBS studies routinely see 30-50% of placebo patients reporting improvement, which makes it difficult for any drug to clearly outperform a sugar pill.

Alverine Combined with Simeticone

The combination formulation has fared considerably better. A large randomized, double-blind, placebo-controlled study found that alverine citrate combined with simeticone was significantly more effective than placebo at relieving abdominal pain and discomfort in IBS patients.⁶ A review of antispasmodic therapies for IBS confirmed this finding, noting the combination’s effectiveness in a large placebo-controlled setting.⁷

Why would adding simeticone, an over-the-counter anti-foaming agent that breaks up gas bubbles, make such a difference? The likely explanation is that bloating and trapped gas are major triggers of pain in IBS, and simeticone addresses a dimension of symptoms that alverine’s muscle relaxation and pain-signal dampening do not. The combination covers more symptom territory than either ingredient alone.

Quality of Life and Real-World Outcomes

Beyond clinical trial endpoints, a pragmatic study compared on-demand use of the alverine citrate/simeticone combination against the usual treatments prescribed by general practitioners for IBS. The results at six months were striking. Patients using the combination saw substantially greater improvement in IBS-specific quality-of-life scores compared to the usual-treatment group. Their IBS symptom severity scores dropped by an average of 170 points versus about 111 in the standard-care arm, and over a third of patients on the combination achieved a symptom severity score below 75, generally considered remission-level, compared with 16% of those receiving usual care.⁸

Improvement in both abdominal pain and bloating was greater in the combination group, and the on-demand approach was associated with lower direct and indirect healthcare costs. That last point matters for IBS, which is a chronic condition that drives a lot of doctor visits, diagnostic testing, and missed workdays. A treatment that works on demand, taken only when symptoms flare, is practically appealing compared to daily medication regimens.

Common Side Effects

Antispasmodics as a class have generally good safety profiles, and alverine citrate fits that pattern.⁷ The most frequently reported side effects are mild and gastrointestinal in nature: nausea, dizziness, headache, and occasionally itching or a rash. These typically resolve quickly and rarely require stopping the drug.

Because alverine works relatively selectively on gut smooth muscle and serotonin receptors in the gut rather than broadly throughout the body, it tends to avoid some of the systemic side effects associated with older antispasmodics. It does not have significant anticholinergic effects, which means you are unlikely to get the dry mouth, blurred vision, urinary retention, or constipation that sometimes come with drugs like hyoscine or dicycloverine. For people who have found those side effects intolerable with other IBS medications, alverine can be a welcome alternative.

Rare Liver Injury

The most serious adverse effect linked to alverine citrate is drug-induced liver injury, though it is rare enough that it appears in the literature primarily as individual case reports rather than as a pattern in clinical trials. Several published cases describe acute hepatitis developing in patients taking alverine, with liver inflammation confirmed by elevated liver enzymes and, in some cases, jaundice.

In one case, a 34-year-old woman was found to have elevated liver function tests during routine screening, and after ruling out other causes, the abnormality was attributed to her alverine citrate use.⁹ In another, a 75-year-old woman developed jaundice and abdominal discomfort while taking the drug; her liver tests returned to normal after stopping it.¹⁰ An earlier case report of a 67-year-old woman noted that the onset and resolution of her hepatitis tracked closely with starting and stopping alverine, and she also developed antinuclear antibodies that followed the course of the liver inflammation. The authors suggested this pointed toward an immune-mediated mechanism.¹¹

These cases are genuinely rare, and alverine-induced hepatitis resolves once the drug is discontinued. Still, they are worth knowing about, especially if you develop unexplained fatigue, dark urine, yellowing of the skin, or upper abdominal discomfort while taking the medication. Your doctor may check liver function if symptoms suggest a problem.

Why the Combination Outperforms Alverine Alone

The consistent pattern in the clinical data, where alverine plus simeticone works and alverine alone does not clearly beat placebo, deserves some unpacking. IBS is not a single symptom but a cluster: pain, bloating, altered bowel habits, and the visceral hypersensitivity that amplifies all of them. Alverine addresses pain and cramping through muscle relaxation and sensory modulation, but it does not do much for the mechanical discomfort of gas distension. Simeticone, by collapsing gas bubbles in the gut lumen, reduces the distension that provokes pain in the first place.

Think of it as reducing both the trigger and the response. Simeticone lowers the physical stimulus (bloating), while alverine reduces the muscular overreaction and the amplified pain signal. Neither alone covers enough of the IBS symptom picture, but together they address the two biggest drivers of day-to-day misery. This is consistent with mechanistic reviews that frame the combination as targeting both motor and sensory pathways in the gut.³

This also explains why the negative trial of alverine alone is not necessarily damning for the combination. The trial was testing the wrong formulation for a multifactorial condition. Researchers and clinicians have increasingly moved toward the combination product, and the standalone capsules have become less commonly prescribed in markets where both are available.

How It Compares to Other IBS Antispasmodics

The IBS antispasmodic market includes several other options, such as mebeverine, hyoscine butylbromide, peppermint oil capsules, and pinaverium. None of them are miracle cures; IBS antispasmodics generally show modest benefit over placebo when looked at across all the evidence, and IBS’s high placebo response rate makes the whole class look weaker in trials than patients sometimes experience in practice.

Alverine’s distinguishing feature, as already discussed, is its dual action on both muscle contraction and serotonin-mediated pain signaling, which gives it a different pharmacological profile from pure muscle relaxants like mebeverine or anticholinergics like hyoscine. Whether that translates to superior real-world outcomes over those alternatives is hard to say definitively, because head-to-head comparisons are limited. The pragmatic trial showing the combination outperforming “usual treatment” at six months is encouraging, but “usual treatment” was a mixed bag of whatever the patient’s doctor typically prescribed.⁸

In practice, IBS treatment often involves trying different antispasmodics until one works for the individual patient. Some people respond well to alverine and poorly to mebeverine, or vice versa, and the reasons are not fully understood. The serotonin receptor component of alverine’s mechanism may make it a particularly reasonable choice for patients whose predominant symptom is pain sensitivity rather than diarrhea or constipation.

Practical Considerations for Taking Alverine Citrate

If you have been prescribed alverine citrate (either alone or in the combination formulation), a few practical points are worth keeping in mind. The drug is typically taken 20-30 minutes before meals, since food triggers many IBS symptoms and pre-treating allows the drug to be active in the gut when the meal arrives. Most prescriptions call for 60 mg or 120 mg capsules taken one to three times daily, though the on-demand approach used in the pragmatic trial, taking it only when symptoms flare, showed strong results and may suit people whose IBS is intermittent rather than constant.

Because alverine is metabolized so rapidly, with peak activity of its metabolite arriving within about 90 minutes, it is not a drug that takes weeks to build up in your system. You should feel whatever benefit it provides relatively quickly. Conversely, if it has not helped after a couple of weeks of consistent use, it probably is not going to start working later.

Alverine is generally not recommended during pregnancy, due to limited safety data rather than known harm, and breastfeeding guidance varies by country. People with a condition called paralytic ileus, where the gut has stopped moving entirely, should not take any antispasmodic. If you have a history of liver disease, the rare case reports of hepatitis suggest a conversation with your doctor is worthwhile before starting.

The Placebo Problem in IBS Research

One of the reasons alverine citrate’s evidence base looks muddled is not unique to this drug: IBS is one of the hardest conditions to study in clinical trials. Placebo response rates in IBS trials routinely hit 40% or higher, which means a drug that genuinely helps a meaningful proportion of patients can still fail to show a statistically significant advantage over placebo. The trial where alverine alone showed a 44% pain reduction versus 33% for placebo illustrates this perfectly. A ten-percentage-point gap is real for the individual patients who benefited, but in a trial with a moderate sample size and a high placebo floor, it gets swallowed by statistical noise.⁵

This does not mean the drug is secretly effective and the trials just missed it. It means that interpreting IBS drug evidence requires accepting some ambiguity. The combination with simeticone cleared the statistical bar; alverine alone did not. For patients and clinicians, the pragmatic question is whether the combination product relieves symptoms in practice, and for a meaningful number of patients, the answer appears to be yes.